In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PerkinElmer Inc.

http://www.perkinelmer.com/

Latest From PerkinElmer Inc.

Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies

Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.

Deal Watch Business Strategies

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology

More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.

Scrip Asks Artificial Intelligence

MTI 100: Global Medtech Recovers Core Growth After A Year Like No Other

With many medtechs restructuring for core growth in the post-pandemic era, Abbott relied on organic growth in 2022 to move to the top of the global medtech ranking. The strength of the US dollar was not kind to companies reporting in local currencies on converting revenues to dollars.

Medtech 100 Commercial
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Drug Discovery Technologies
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Analytica of Branford, Inc.
    • Arnel Inc.
    • BioLegend, Inc.
    • Haoyuan Biotech Co. Ltd.
    • Immunodiagnostic Systems Holdings PLC
    • Opto Technology, Inc.
    • Perten Instruments
    • SYM-BIO Lifescience
    • Tulip Diagnostics Private Limited
    • Wallac Oy
    • Vanadis Diagnostics, AB
    • ViaCell
    • Oxford Immunotec Global PLC
UsernamePublicRestriction

Register